Acute lymphoblastic leukemia (ALL) is the second most common acute leukemia in adults,
with an incidence of over 6500 cases per year in the United States alone. The hallmark of …

Acute lymphoblastic leukemia (ALL) is a cancer-specific lymphoid cell. Induction and
consolidation chemotherapy alone or in combination with different therapeutic approaches …

Background In a single-center phase 1–2a study, the anti-CD19 chimeric antigen receptor
(CAR) T-cell therapy tisagenlecleucel produced high rates of complete remission and was …

Chimeric antigen receptor (CAR) T cells targeting CD19 mediate potent effects in relapsed
and/or refractory pre–B cell acute lymphoblastic leukemia (B-ALL), but antigen loss is a …

Background: Cancer is one of the leading causes of death worldwide. Over the years, a
number of conventional cytotoxic approaches for neoplastic diseases has been developed …

The immune system evolved to distinguish non-self from self to protect the organism. As
cancer is derived from our own cells, immune responses to dysregulated cell growth present …

T cells engineered to express chimeric antigen receptors (CARs) that are specific for tumour
antigens have led to high complete response rates in patients with haematologic …

Potent CD19-directed immunotherapies, such as chimeric antigen receptor T cells (CART)
and blinatumomab, have drastically changed the outcome of patients with …

Chimeric antigen receptor (CAR)-engineered T cells (CAR-T cells) have yielded
unprecedented efficacy in B cell malignancies, most remarkably in anti-CD19 CAR-T cells …

Tisagenlecleucel (CTL019) is an investigational immunotherapy that involves
reprogramming a patient's own T cells with a transgene encoding a chimeric antigen …